MX2013006758A - Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. - Google Patents

Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.

Info

Publication number
MX2013006758A
MX2013006758A MX2013006758A MX2013006758A MX2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A MX 2013006758 A MX2013006758 A MX 2013006758A
Authority
MX
Mexico
Prior art keywords
methods
prostate
hla
binding peptides
peptides derived
Prior art date
Application number
MX2013006758A
Other languages
English (en)
Spanish (es)
Inventor
Toni Weinschenk
Peter Lewandrowski
Stefan Stevanovic
Cecile Gouttefanges
Hans-Georg Rammensee
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/fr
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MX2013006758A publication Critical patent/MX2013006758A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2013006758A 2010-12-14 2011-11-14 Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. MX2013006758A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/069675 WO2011073215A2 (fr) 2009-12-14 2010-12-14 Peptides se liant aux hla, dérivés de molécules antigéniques associées à la prostate, et leurs procédés d'utilisation
PCT/EP2011/070024 WO2012079878A2 (fr) 2010-12-14 2011-11-14 Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés

Publications (1)

Publication Number Publication Date
MX2013006758A true MX2013006758A (es) 2013-08-01

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006758A MX2013006758A (es) 2010-12-14 2011-11-14 Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.

Country Status (9)

Country Link
JP (1) JP6032853B2 (fr)
KR (1) KR20130126671A (fr)
CN (1) CN103547283A (fr)
AU (1) AU2011344652B2 (fr)
CA (1) CA2821582A1 (fr)
MX (1) MX2013006758A (fr)
NZ (1) NZ609916A (fr)
SG (1) SG191154A1 (fr)
WO (1) WO2012079878A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
CN106456784A (zh) * 2014-04-16 2017-02-22 拜康有限公司 包含摩尔过量的山梨醇的稳定蛋白质制剂
CA3172801A1 (fr) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Procede de traitement de cancer a l'aide de lymphocytes t genetiquement modifies
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
CA3053133A1 (fr) * 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Methodes et compositions reposant sur le hla et leurs utilisations
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1244465A4 (fr) * 1999-12-21 2005-01-12 Epimmune Inc Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20030235533A1 (en) * 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
US20060205934A1 (en) * 2002-12-05 2006-09-14 Macina Roberto A Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (fr) * 2003-04-25 2005-04-14 Epimmune Inc. Constructions multi-epitope optimisees et leurs utilisations
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
NO2119726T3 (fr) * 2008-05-14 2015-05-23
EP2172211B1 (fr) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers

Also Published As

Publication number Publication date
SG191154A1 (en) 2013-07-31
WO2012079878A3 (fr) 2012-08-09
CN103547283A (zh) 2014-01-29
AU2011344652A1 (en) 2013-05-23
WO2012079878A2 (fr) 2012-06-21
KR20130126671A (ko) 2013-11-20
JP6032853B2 (ja) 2016-11-30
NZ609916A (en) 2015-03-27
JP2014502961A (ja) 2014-02-06
CA2821582A1 (fr) 2012-06-21
AU2011344652B2 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
WO2011073215A3 (fr) Peptides se liant aux hla, dérivés de molécules antigéniques associées à la prostate, et leurs procédés d'utilisation
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX2011010977A (es) Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
NZ603271A (en) Anti-erbb3 antibodies
EA201290901A1 (ru) Фитоканнабиноиды для лечения злокачественной опухоли
NZ707086A (en) Anti-cd40 antibodies and methods of use
WO2012006634A3 (fr) Thérapie peptidique par antigène prostatique spécifique (psa)
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ631197A (en) Anti sez6 antibodies and methods of use
NZ606195A (en) Methods and compositions for liver cancer therapy
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
SG10201903119QA (en) Polypeptide vaccine
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX346450B (es) Composiciones y métodos para el tratamiento de la enfermedad celíaca.
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
MX2011010955A (es) Terapia complementaria contra el cancer.
MX350661B (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
WO2012170776A3 (fr) Procédés de détermination du pronostic d'un patient pour la récurrence d'un cancer de la prostate et/ou déterminer une évolution de traitement pour un cancer de la prostate après une prostatectomie radicale
EA201370071A1 (ru) Способы и композиции для лечения рака легких
EA201200999A1 (ru) Способы лечения рака молочной железы
GEP201706612B (en) Methods for the treatment of breast cancer
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
DK2252322T3 (da) Vaccinesammensætninger